Advertisement

Mycopathologia

, Volume 183, Issue 6, pp 905–912 | Cite as

Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum

  • Zoltán Tóth
  • Tamás Kardos
  • Renátó Kovács
  • Gábor Kardos
  • Fruzsina Nagy
  • Eszter Prépost
  • Zsolt Barta
  • István Takacs
  • László MajorosEmail author
Original Paper
  • 108 Downloads

Abstract

Currently echinocandins are recommended in Candida peritonitis and pleuritis. We determined micafungin killing rates (k values) at therapeutic concentrations (0.25–2 mg/L) in RPMI-1640 with and without 10 and 30% serum mimicking in vivo conditions against six Candida species isolated from peritoneal and pleural fluid. In RPMI-1640, micafungin was fungicidal against C. glabrata, C. krusei and C. kefyr within 2.27 ± 10.68, 2.69 ± 10.29 and 3.10 ± 4.41 h, respectively, while was fungistatic against C. albicans, C. tropicalis and C. parapsilosis. In 10% serum, ≥ 0.25, ≥ 0.5, ≥ 0.5 and ≥ 1 mg/L micafungin produced positive k values (killing) for all C. albicans, C. glabrata, C. kefyr and C. krusei, respectively. In 30% serum, 2 mg/L micafungin produced killing against all C. albicans, C. glabrata and C. kefyr isolates, but was ineffective against C. krusei, C. parapsilosis and 2 of 3 C. tropicalis. Micafungin exposure should be increased against non-albicans species to eradicate fungi from peritoneal and pleural cavities.

Keywords

Candida peritonitis Candida pleuritis Echinocandins Non-albicans Candida species 

Notes

Acknowledgements

L. Majoros received conference travel grants from MSD, Astellas and Pfizer.

References

  1. 1.
    Perlin DS. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs. 2014;74:1573–85.CrossRefGoogle Scholar
  2. 2.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–50.CrossRefGoogle Scholar
  3. 3.
    Nasar A, Ryan L, Frei CR, Cota JM, Wiederhold NP. Influence of serum and albumin on echinocandin in vitro potency and pharmacodynamics. Curr Fungal Infect Rep. 2013;7:89–95.CrossRefGoogle Scholar
  4. 4.
    Saleh Q, Kovács R, Kardos G, Gesztelyi R, Kardos T, Bozó A, et al. Decreased killing activity of micafungin against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the presence of human serum. Microb Drug Resist. 2017;23:764–70.CrossRefGoogle Scholar
  5. 5.
    Földi R, Szilágyi J, Kardos G, Berényi R, Kovács R, Majoros L. Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology. Diagn Microbiol Infect Dis. 2012;73:338–42.CrossRefGoogle Scholar
  6. 6.
    Kovács R, Gesztelyi R, Berényi R, Domán M, Kardos G, Juhász B, et al. Killing rates exerted by caspofungin in 50% serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and C. inconspicua. J Med Microbiol. 2014;63:186–94.CrossRefGoogle Scholar
  7. 7.
    Földi R, Kovács R, Gesztelyi R, Kardos G, Berényi R, Juhász B, et al. Comparison of in vitro and in vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans. Mycopathologia. 2012;174:311–8.CrossRefGoogle Scholar
  8. 8.
    Szilágyi J, Földi R, Bayegan S, Kardos G, Majoros L. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology. J Chemother. 2012;24:18–25.CrossRefGoogle Scholar
  9. 9.
    Kovács R, Saleh Q, Bozó A, Tóth Z, Gesztelyi R, Kardos T, Kardos G, Takacs I, Majoros L. Killing activity of micafungin against Candida albicans, C. dubliniensis and Candida africana in the presence of human serum. Mycopathologia. 2017;182:979–87.CrossRefGoogle Scholar
  10. 10.
    Yamada N, Kumada K, Kishino S, Mochizuki N, Ohno K, Ogura S. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother. 2011;17:731–4.CrossRefGoogle Scholar
  11. 11.
    Grau S, Luque S, Campillo N, Samsó E, Rodríguez U, García-Bernedo CA, et al. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother. 2015;70:2854–61.CrossRefGoogle Scholar
  12. 12.
    García-de-Lorenzo A, Luque S, Grau S, Agrifoglio A, Cachafeiro L, Herrero E, et al. Comparative population plasma and tissue pharmacokinetics of micafungin in critically ill patients with severe burn injuries and patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60:5914–21.CrossRefGoogle Scholar
  13. 13.
    Zhao Y, Prideaux B, Nagasaki Y, Lee MH, Chen PY, Blanc L, et al. Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother. 2017;61:e01009–17.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Moriyama B, Ditullio M, Wilson E, Henning SA, Penzak SR, Danner RL, et al. Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema. Antimicrob Agents Chemother. 2011;55:2478–80.CrossRefGoogle Scholar
  15. 15.
    Clinical and Laboratory Standards Institute. 2008: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.Google Scholar
  16. 16.
    Huang LL, Xia HH, Zhu SL. Ascitic fluid analysis in the differential diagnosis of ascites: focus on cirrhotic ascites. J Clin Transl Hepatol. 2014;2:58–64.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Ferreiro L, Porcel JM, Valdés L. Diagnosis and management of pleural transudates. Arch Bronconeumol. 2017;53:629–36.PubMedGoogle Scholar
  18. 18.
    Porcel JM, Light RW. Diagnostic approach to pleural effusion in adults. Am Fam Physician. 2006;73:1211–20.PubMedGoogle Scholar
  19. 19.
    Tarn AC, Lapworth R. Biochemical analysis of ascitic (peritoneal) fluid: what should we measure? Ann Clin Biochem. 2010;47:397–407.CrossRefGoogle Scholar
  20. 20.
    Wahidi MM, Willner DA, Snyder LD, Hardison JL, Chia JY, Palmer SM. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest. 2009;135:484–91.CrossRefGoogle Scholar
  21. 21.
    Davies HE, Davies RJ, Davies CW, BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii41–53.CrossRefGoogle Scholar
  22. 22.
    Srinivasnakshatri VK, Subramani P, Venkateshwaraprasad KN, Varma P. A fatal case of fungal empyema due to Candida krusei and Candida tropicalis: a rare occurrence with an atypical presentation. J Clin Diagn Res. 2014;8:DD01–2.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol. 2011;49:3800–4.CrossRefGoogle Scholar
  24. 24.
    Vergidis P, Clancy CJ, Shields RK, Park SY, Wildfeuer BN, Simmons RL, et al. Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS ONE. 2016;11:e0153247.CrossRefGoogle Scholar
  25. 25.
    Bassetti M, Righi E, Ansaldi F, Merelli M, Scarparo C, Antonelli M, Garnacho-Montero J, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015;41:1601–10.CrossRefGoogle Scholar
  26. 26.
    Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O, The AmarCand study group. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061–7.CrossRefGoogle Scholar
  27. 27.
    Ko SC, Chen KY, Hsueh PR, Luh KT, Yang PC. Fungal empyema thoracis: an emerging clinical entity. Chest. 2000;117:1672–8.CrossRefGoogle Scholar
  28. 28.
    Lin HS, Chao CM, Lin WT, Lai CC. Candida empyema thoracis at a hospital in Taiwan. Surg Infect (Larchmt). 2014;15:540–3.CrossRefGoogle Scholar
  29. 29.
    Nigo M, Vial MR, Munita JM, Jiang Y, Tarrand J, Jimenez CA, et al. Fungal empyema thoracis in cancer patients. J Infect. 2016;72:615–21.CrossRefGoogle Scholar
  30. 30.
    Pemán J, Aguilar G, Valía JC, Salavert M, Navarro D, Zaragoza R, et al. Jávea consensus guidelines for the treatment of Candida peritonitis and other intra-abdominal fungal infections in non-neutropenic critically ill adult patients. Rev Iberoam Micol. 2017;34:130–42.CrossRefGoogle Scholar
  31. 31.
    Bordallo-Cardona MÁ, Escribano P, Marcos-Zambrano LJ, Díaz-García J, de la Pedrosa EG, Cantón R, et al. Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata. Med Mycol. 2017.  https://doi.org/10.1093/mmy/myx124.CrossRefGoogle Scholar
  32. 32.
    Shields RK, Nguyen MH, Press EG, Clancy CJ. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother. 2014;58:7601–5.CrossRefGoogle Scholar
  33. 33.
    Fekkar A, Meyer I, Brossas JY, Dannaoui E, Palous M, Uzunov M, et al. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother. 2013;57:2380–2.CrossRefGoogle Scholar
  34. 34.
    Xiao M, Fan X, Hou X, Chen SC, Wang H, Kong F, et al. Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant Candida tropicalis and Candida glabrata isolates with delineation of their resistance mechanisms. Infect Drug Resist. 2018;11:155–61.CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Zoltán Tóth
    • 1
  • Tamás Kardos
    • 1
    • 2
  • Renátó Kovács
    • 1
    • 3
  • Gábor Kardos
    • 1
  • Fruzsina Nagy
    • 1
  • Eszter Prépost
    • 1
  • Zsolt Barta
    • 4
  • István Takacs
    • 5
  • László Majoros
    • 1
    Email author
  1. 1.Faculty of Medicine, Medical MicrobiologyUniversity of DebrecenDebrecenHungary
  2. 2.Department of Pulmonology, Faculty of MedicineUniversity of DebrecenDebrecenHungary
  3. 3.Faculty of PharmacyUniversity of DebrecenDebrecenHungary
  4. 4.Department of Infectology, Faculty of MedicineUniversity of DebrecenDebrecenHungary
  5. 5.Faculty of HealthUniversity of MiskolcMiskolcHungary

Personalised recommendations